Sol-Gel Technologies Ltd. has reported its financial results for the third quarter of 2026, marking a pivotal moment for the company as it nears the completion of its Phase 3 clinical trial for SGT-610 (patidegib gel, 2%). This update is crucial not only for Sol-Gel but also for the broader pharmaceutical preparations industry, as it may influence market dynamics surrounding dermatological treatments.

Founded in 2015 and traded on the Nasdaq under the ticker SLGL, Sol-Gel Technologies is a dermatology company focused on developing innovative therapies for rare skin diseases. The company specializes in pharmaceutical preparations, particularly treatments for conditions like Gorlin syndrome, which is characterized by a predisposition to basal cell carcinoma. Recent filings include a 6-K on November 12, 2026, detailing the latest financial performance and corporate updates.

The latest filing indicates that Sol-Gel has reached a significant milestone in its clinical research. It states, "On September 17, 2026, Sol-Gel announced that the last patient had completed the last scheduled study visit in its pivotal Phase 3 clinical trial (SGT-610-01) for the prevention of basal cell carcinoma (BCC) lesions in adult patients with Gorlin syndrome." This trial enrolled 113 patients, with 102 completing the study, reflecting a completion rate of approximately 90%.

Financially, Sol-Gel reported nominal revenue for the third quarter of 2026, down from $0.4 million in the same period in 2025. The company incurred research and development expenses of $5.1 million, a decrease from $5.7 million year-over-year, attributed primarily to reduced clinical trial costs related to SGT-610. Sol-Gel's net loss for the quarter was $5.6 million, compared to a loss of $5.9 million in the prior year.

As of September 30, 2026, Sol-Gel had $14.4 million in cash and cash equivalents and $31.3 million in marketable securities, totaling $45.7 million. The company anticipates that these resources will sustain its operations into the first quarter of 2028.

Mr. Mori Arkin, Executive Chairman of Sol-Gel, emphasized the importance of the trial's completion, stating, "The third quarter brought us to the threshold of the most important moment in Sol-Gel's history." He noted that the company is also preparing for potential commercialization of SGT-610, contingent on positive clinical results and regulatory approval.

In addition to the clinical trial updates, Sol-Gel hosted a Key Opinion Leader (KOL) Investor Event in New York on October 14, 2026, featuring dermatology experts who discussed the implications of Gorlin syndrome and the potential benefits of SGT-610 in preventing new BCCs.

Looking ahead, Sol-Gel is advancing its U.S. commercial readiness activities for SGT-610. The company plans to retain full U.S. commercial rights and aims to utilize a cost-effective model for commercialization, reaching the specific treating population through a focused field organization supported by outsourced infrastructure.

Details regarding the next steps following this filing were not specified, but the company is expected to report top-line results from its Phase 3 trial by late November 2026. This outcome could significantly impact Sol-Gel's market position and the competitive landscape in the pharmaceutical preparations sector.